Does the type of disease-modifying drugs impact on the quality of life in patients with relapsing-remitting multiple sclerosis?
Objective. Multiple sclerosis (MS) can cause serious physical and mental problems, which can affect patients’ health-related quality of life (HQoL). The aims of this study are comparing oral and injection disease-modifying drugs (DMDs) in improving HQoL and researching the relations between demogra...
Main Authors: | Amirreza Naseri, Ehsan Nasiri, Malihe Talebi, Kimia Karimi, Mahnaz Talebi |
---|---|
Format: | Article |
Language: | English |
Published: |
Amaltea Medical Publishing House
2020-09-01
|
Series: | Romanian Journal of Neurology |
Subjects: | |
Online Access: | https://rjn.com.ro/articles/2020.3/RJN_2020_3_Art-06.pdf |
Similar Items
-
Predominant domains and associated demographic and clinical characteristics in multiple sclerosis-related cognitive impairment in mildly disabled patients
by: Mahnaz Talebi, et al.
Published: (2022-05-01) -
Advances in the treatment of relapsing - Remitting multiple sclerosis
by: Radu Tanasescu, et al.
Published: (2014-04-01) -
Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
by: Iciar Martínez-López, et al.
Published: (2020-04-01) -
Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
by: Virender Bhan, et al.
Published: (2023-08-01) -
Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary‐progressive and relapsing‐remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases
by: Priyadarshi Prajjwal, et al.
Published: (2023-07-01)